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Abstract
The prevalence and spectrum of germline mutations in BRCA1 and BRCA2 have been reported in
single populations, with the majority of reports focused on White in Europe and North Amer-
ica. The Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA) has assembled data on
18,435 families with BRCA1 mutations and 11,351 families with BRCA2 mutations ascertained
from69 centers in 49 countries on six continents. This study comprehensively describes the char-
acteristics of the 1,650 unique BRCA1 and 1,731 unique BRCA2 deleterious (disease-associated)
mutations identified in the CIMBA database. We observed substantial variation in mutation type
and frequency by geographical region and race/ethnicity. In addition to known founder muta-
tions, mutations of relatively high frequencywere identified in specific racial/ethnic or geographic
groups that may reflect founder mutations and which could be used in targeted (panel) first pass
genotyping for specific populations. Knowledge of the population-specific mutational spectrum
in BRCA1 and BRCA2 could inform efficient strategies for genetic testing and may justify a more
broad-based oncogenetic testing in some populations.
K EYWORD S
BRCA1, BRCA2, breast cancer, ethnicity, geography, mutation, ovarian cancer
1 INTRODUCTION
Women who carry germline mutations in either BRCA1 [MIM#
113705] or BRCA2 [MIM# 600185] are at an increased risk of breast
and ovarian cancers. Estimates of cancer risk associated with BRCA1
and BRCA2 mutations vary depending on the population studied. For
mutations in BRCA1, the estimated average risk of breast and ovar-
ian cancers ranges from 57 to 65% and 20 to 50%, respectively (Chen
& Parmigiani, 2007; Kuchenbaecker et al., 2017). For BRCA2, average
risk estimates range from 35 to 57% and 5 to 23%, respectively (Chen
& Parmigiani, 2007; Kuchenbaecker et al., 2017). Mutation-specific
cancer risks have been reported that suggest breast cancer cluster
regions (BCCR) andovarian cancer cluster regions (OCCR)exist inboth
BRCA1 and BRCA2 (Gayther et al., 1997; Kuchenbaecker et al., 2017;
Rebbeck et al., 2015). The identification of mutations in BRCA1 or
BRCA2 has important clinical implications, as knowledge of their pres-
ence is important for risk assessment and informs medical manage-
ment for patients. Interventions, such as risk-reducing bilateral mas-
tectomy and salpingo-oophorectomy or annual breast magnetic res-
onance imaging (MRI) screening, are available to women who carry
deleterious BRCA1 or BRCA2 mutations to enable early detection of
breast cancer and for active risk reduction by risk-reducing surgery
(Domchek et al., 2010; Rebbeck et al., 2002; Saslow et al., 2007).
The presence of BRCA1 or BRCA2 mutations can also influence can-
cer treatment decisions, principally around the use of platinum agents
or poly(ADP-ribose) polymerase (PARP) inhibitors (Lord & Ashworth,
2017) or contralateral risk-reducing mastectomy. Increased numbers
of women are having clinical genetic testing for BRCA1 and BRCA2
mutations, and recommendations continue to expand to whom testing
should be offered (NCCN, 2017).
In Whites drawn from the general populations in North America
and the United Kingdom, the prevalence of BRCA1 and BRCA2 muta-
tions has been estimated around a broad range from 0.1 to 0.3% and
0.1 to 0.7%, respectively (Peto et al., 1999; Struewing et al., 1997;
Whittemore et al., 2004). The Australian Lifepool study, studying a
control population consisting of cancer-free women ascertained via
population-based mammographic screening program, estimated the
overall frequency of BRCA1 and BRCA2mutations to be 0.65% (1:153),
withBRCA1mutations at 0.20% (1:500) andBRCA2mutations at 0.45%
(1:222) (Thompson et al., 2016). Estimates from the Exome Aggrega-
tion Consortium (ExAC) are similar, with frequencies of BRCA1 and
BRCA2mutations (excludingTheCancerGenomeAtlas [TCGA]data) at
0.21% (1:480) and 0.31% (1:327), respectively; or combined at 0.51%
(1:195) (Maxwell, Domchek, Nathanson, & Robson, 2016). As they do
not include large genomic rearrangements, some newer population-
based estimates may still underrepresent the total number of BRCA1
and BRCA2 mutations. Although the overall prevalence of BRCA1 and
BRCA2mutations inmost general populations is low,many hundreds of
thousandsof yet-to-be-tested individualsworldwide carry thesemuta-
tions.
The prevalence of founder mutations in some racial/ethnic groups
is much higher. For example, the mutations BRCA1 c.5266dup
(5382insC), BRCA1 c.68_69del (185delAG) and BRCA2 c.5946del
(6174delT) have a combined prevalence of 2–3% in U.S. Ashkenazi
Jews (Roa,Boyd,Volcik,&Richards, 1996; Struewinget al., 1997;Whit-
temore et al., 2004). For these mutations, double heterozygotes in
BRCA1 and BRCA2 also have been reported (Friedman et al., 1998;
Moslehi et al., 2000; Ramus et al., 1997a; Rebbeck et al., 2016). Several
other founder mutations have been identified, including the Icelandic
founder mutation BRCA2 c.771_775del (999del5) (Thorlacius et al.,
1996), the French Canadian mutations BRCA1 c.4327C > T (C4446T),
the BRCA2 c.8537_8538del (8765delAG) (Oros et al., 2006b; Tonin
et al., 2001; Tonin, Mes-Masson, Narod, Ghadirian, & Provencher,
1999), the BRCA1 mutations c.181T > G, and c.4034del in Central-
Eastern Europe (Gorski et al., 2000), the BRCA1 c.548-?−4185+?del
in Mexico (Villarreal-Garza et al., 2015b; Weitzel et al., 2013),
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the BRCA2 mutation c.9097dup in Hungary (Ramus et al., 1997b; Van
Der Looij, et al., 2000), and others. These mutations represent the
majority of mutations observed in these populations and have been
confirmed as true founder mutations as they have common ances-
tral haplotypes (Neuhausen et al., 1996, 1998; Oros et al., 2006a).
Recurrent mutations have been identified in other populations, but
they represent a smaller proportion of all unique BRCA1 and BRCA2
mutations, and have not been characterized as true founder muta-
tions. There are multiple recurrent mutations in Scandinavian, Dutch,
French, and Italian populations (Ferla et al., 2007). Similarly, a number
of recurrentmutations specific to non-European populations also have
been reported in Hispanic/Mexican, African American, Middle East-
ern, and Asian populations (Bu et al., 2016; Ferla et al., 2007; Kurian,
2010; Lang et al., 2017; Ossa & Torres, 2016; Villarreal-Garza et al.,
2015b).
The mutational spectra in BRCA1 and BRCA2 are best delineated
in Whites from Europe and North America. However, data on muta-
tional spectra in non-White populations of Asian, African, Mediter-
ranean, South American andMexican Hispanic descent have also been
reported (Abugattas et al., 2015; Ahn et al., 2007; Alemar et al., 2016;
Bu et al., 2016; Eachkoti et al., 2007; Ferla et al., 2007; Gao et al., 2000;
Gonzalez-Hormazabal et al., 2011; Ho et al., 2000; Jara et al., 2006;
John et al., 2007; Kurian, 2010; Laitman et al., 2011; Lang et al., 2017;
Lee et al., 2003; Li, et al., 2006;Nanda et al., 2005;Ossa&Torres, 2016;
Pal, Permuth-Wey, Holtje, & Sutphen, 2004; Rodríguez et al., 2012;
Seong et al., 2009; Sharifah et al., 2010; Solano et al., 2017; Song et al.,
2005; Song et al., 2006; Tohet al., 2008; Torres et al., 2007; Troudi et al.,
2007; Villarreal-Garza et al., 2015b; Vogel et al., 2007; Weitzel et al.,
2005;Weitzel et al., 2007; Zhang et al., 2009). In the current study, we
provide a global description of BRCA1 and BRCA2 mutations by geog-
raphy and race/ethnicity from the investigators of the Consortium of
Investigators ofModifiers of BRCA1/2 (CIMBA).
2 METHODS
Details of centers participating in CIMBA and data collection proto-
cols have been reported previously (Antoniou et al., 2007). Details
of the CIMBA initiative and information about the participating cen-
ters can be found at http://cimba.ccge.medschl.cam.ac.uk/ (Chenevix-
Trench et al., 2007). All includedmutation carriers participated in clini-
cal or research studies at the host institutions after providing informed
consent under IRB-approved protocols. Sixty-nine centers and mul-
ticenter consortia submitted data that met the CIMBA inclusion cri-
teria (Antoniou et al., 2007). Only female carriers with pathogenic
BRCA1 and/or BRCA2 mutations were included in the current anal-
ysis. One mutation carrier per family in the CIMBA database was
included in this report. The actual family relationships (e.g., pedigrees)
were not available, but a variable that defined family membership sup-
plied by each center was used for this purpose. Less than 1% of fami-
lies (86 of 29,700) had two family members with two different muta-
tions. In these situations, each mutation observed in the family was
included in theanalysis. In the caseof the94dualmutation carriers (i.e.,
individuals with both BRCA1 and BRCA2 mutations), one of the two
mutations was chosen at random for inclusion in the analysis.
The CIMBA data set was used to describe the distribution of
mutations by effect and function. For the remaining analyses, muta-
tions were excluded if self-reported race/ethnicity data were miss-
ing. Pathogenicity of mutation was defined as follows: (1) generating
a premature termination codon (PTC), except variants generating a
PTC after codon 1854 in BRCA1 and after codon 3309 of BRCA2, (2)
large in-frame deletions that span one or more exons, and (3) dele-
tion of transcription regulatory regions (promoter and/or first exon)
expected to cause lack of expression ofmutant allele.We also included
missense variants considered pathogenic by using multifactorial likeli-
hood approaches (Bernstein et al., 2006; Goldgar et al., 2004). Muta-
tions that did not meet the above criteria but have been classified
as pathogenic by Myriad Genetics, Inc. (Salt Lake City, UT) also were
included. Classification of nonsense-mediated decay (NMD)was based
on in-silico predictions and was not based on molecular classification
(Anczukow et al., 2008).
Contingency table analysis using a chi-square test was used to test
for differences in dichotomous variables, as was a t-test for continu-
ous variables. Mutation counts are presented as the number of fami-
lies with the mutation. Fisher's exact tests were used if sample sizes in
any contingency table cell were less than five. Analyses were done in
STATA, v. 14.2.
3 RESULTS
3.1 Mutations in BRCA1 and BRCA2
From the 26,861 BRCA1 and 16,954 BRCA2 mutation carriers in
the CIMBA data set as of June 2017, 18,435 families with BRCA1
mutations and 11,351 families with BRCA2 mutations were stud-
ied to count only one occurrence of a mutation per family. Fig-
ure 1 shows the countries that contributed mutations to this report.
From among these families, 1,650 unique BRCA1 and 1,731 unique
BRCA2 mutations were identified. The unique mutations and num-
ber of families in which each mutation was observed are listed in
Supporting Information Table S1. In each gene, the five most com-
mon mutations (including founder mutations) accounted for 33% of
all mutations in BRCA1 (8,739 of 26,861 mutation carriers) and 19%
of all mutations in BRCA2 (3,244 of 16,954 mutation carriers). A
website containing information about the most common mutations
reported here can be found at: http://cimba.ccge.medschl.cam.ac.uk/.
This information may be periodically updated as new data become
available.
3.2 Mutation type and effect
Table 1 presents a summary of the type of BRCA1 or BRCA2 muta-
tions and their predicted effect on transcription and translation. The
most commonmutation typewas frameshift followedbynonsense. The
most common effect of BRCA1 and BRCA2 mutations was premature
translation terminationandmostof themutantmRNAswerepredicted
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F IGURE 1 Countries (in red) that provided data on BRCA1 and/or BRCA2 mutation carriers in this report. Race/ethnic breakdown is reported
for countries withmore than 100 observations withmultiple ethnicities totaling at least 10% of the country's sample (i.e., Australia, Brazil, Canada,
USA)
to undergo nonsense-mediated mRNA decay (Anczukow et al., 2008).
Despite having the same spectrum of mutations in BRCA1 and BRCA2,
the frequency distribution by mutation type, effect, or function dif-
fered significantly (p < .05) between BRCA1 and BRCA2mutation car-
riers for many groups, as shown in Table 1. These observed differences
are largely because genomic rearrangements and missense mutations
account for a much higher proportion of mutations in BRCA1 when
comparedwith BRCA2, as previously described (Welcsh &King, 2001).
We and others have found that BCCR and OCCR exist that may
confer differential cancer risks (Gayther et al., 1997; Gayther et al.,
1995; Kuchenbaecker et al., 2017; Rebbeck et al., 2015). Figure 2
reports the relative frequency of mutations in the BCCR and OCCR
by race/ethnicity. Compared with Whites, we observed differences in
the relative frequency of mutations in the BRCA1 BCCR and OCCR
in Asians and Hispanics, and in the BRCA2 OCCR in Hispanics. To the
degree that the mutations within the BCCRs and OCCRs conferred
differential cancer risks, these data suggest that BRCA1 and BRCA2
mutation-associated cancer risks may vary by race/ethnicity.
3.3 Geography and race/ethnicity
The most common mutations by country are summarized in Table 2
(BRCA1) and Table 3 (BRCA2). The locations of the mutations that
were observed in African American, Asian, and Hispanic populations
are depicted in Figure 3 (BRCA1) and Figure 4 (BRCA2). Some coun-
tries (Albania, Bosnia, Costa Rica, Ireland, Honduras, Japan, Norway,
Peru, Philippines,Qatar, Saudi Arabia, Romania, Venezuela andTurkey)
contributed fewer than 10 mutation carriers to the CIMBA database.
Many of these mutations were submitted to the central database by
CIMBA centers that ascertained these patients, but these patients
originated from a different country. Based on such small numbers, it
was impossible to make inferences about the relative importance of
mutations in these locations. A description of the major ethnicity by
country is provided in Supporting Information Table S2.
The mutational distribution among the major racial/ethnic groups
andby geography is summarized in Tables 4 and5. Table 4 includes only
those individuals forwhomself-identified race/ethnicitywas recorded.
Note that in some countries it is prohibited to collect data on race and
ethnicity, so this information is missing. Among the 10 most common
BRCA1 mutations in each racial/ethnic group, a few were seen in sev-
eral populations, including the recurrent Jewish and Eastern European
founder mutations c.5266dup (5382insC) and c.68_69del (185delAG),
c.815_824dup in African Americans and Hispanics, c.3756_3759del in
White and Jewish individuals, and c.5503C > T and c.3770_3771del
in Asians and Jews. Similarly, recurrent mutations in BRCA2 included
c.5946del (6174delT) in Whites and Jews, c.2808_2811del in Whites,
African Americans, Asians, Hispanics, and Jews, c.6275_6276del
in Whites and Hispanics, c.3847_3848del in Whites and Jews,
c.658_659del in African Americans and Hispanics, and c.3264dup in
Hispanics and Jews. Themajority of other recurrentBRCA1 andBRCA2
mutations were only observed within a single racial/ethnic group, par-
ticularly African Americans, Asians, and Hispanics. Of note, the vast
majority of women who self-identified as Jewish carry the Ashke-
nazi Jewish founder mutations BRCA1 c.5266dup and c.68_69del and
BRCA2 c.5946del. Only 72 (3.9%) of 1,852 BRCA1 mutation carrier
families and 55 (5.6%) of 990 BRCA2 mutation carrier families who
self-identified as being Jewish carried other (nonfounder) mutations.
However, since many individuals of self-identified Jewish ancestry are
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TABLE 1 Characteristics of BRCA1 and BRCA2mutations in the CIMBA database (by uniquemutation)
BRCA1 (N= 1,650) BRCA2 (N= 1,731)
Designation Definition N % N % p-value
Mutation Type Large Deletion (DL) Genomic DNA deletion (encompassing at
least 1 exon)
130 7.9 34 1.9 <.0001
Large Duplication (DP) Genomic DNA duplication (encompassing at
least 1 exon)
27 1.6 11 0.6 .010
Frameshift (FS) Deletion or insertion resulting in a
disruption of the open reading frame
948 57.5 1,141 65.9 <.0001
In-FrameDeletion (IFD) Small deletions, splice site mutations or
large genomic rearrangements that result
in a change in themRNA but do not
change the open reading frame
1 <0.1 2 0.1 .518
Missense (MS) Results in an altered amino acid 46 2.8 13 0.8 .0001
Nonsense (NS) Point mutation resulting in a stop codon 313 19.0 380 22.0 .027
Splice (SP) Results in aberrant RNA splicing 166 10.1 131 7.6 .013
Multiple Types
(including those listed
above)
20 1.1 19 1.1 1.00
Mutation Effect No RNA Mutation is predicted to abrogate RNA
production
21 1.3 6 0.3 .003
Premature Termination
Codon (PTC)
Result of a nonsense substitution,
frameshift due to small deletion or
insertion, aberrant splicing, or large
genomic rearrangement
1,331 81.0 1,542 89.0 <.0001
Unknown/Other Unknown effect 298 18.0 183 10.6 <.0001
Mutation
Function
Nonsense-Mediated
Decay (NMD)a
(Anczukow et al.,
2008)
Mutation is predicted to result in reduced
transcript level due to decay of RNA
and/or degradation/instability of
truncated proteins
1,213 73.9 1,523 88.0 <.0001
NoNMD Mutations generating a premature stop
codon in the first or last exon that is
predicted not to result in NMD
58 3.5 16 0.9 <.0001
No RNA Loss of expression due to deletion of
promoter and/or transcription start site
21 1.3 6 0.4 .003
Re-Initiation Mutations presumed to result in translation
re-initiation but produce unstable protein
4 0.2 0 0.0 .294
NMD/Re-initiation Mutations presumed to result in translation
re-initiation but produce unstable protein
60 3.7 0 0.0 –
Unknown/Other Unknown function 294 17.8 187 10.7 <.0001
Mutation Class 1 Mutations predicted to be associated with
unstable or no protein
1,298 78.6 1,529 88.3 <.0001
2 Mutations predicted to be associated with
stable mutant proteins
112 6.8 36 2.1 <.0001
3 Unknown function 240 14.6 167 9.6 <.0001
P-values reflect the comparison of frequencies between BRCA1 and BRCA2mutation carriers.
aReferences (Anczukow et al., 2008; Buisson, et al., 2006;Mikaelsdottir, et al., 2004; Perrin-Vidoz, et al., 2002;Ware, et al., 2006)
only tested for the three founder mutations, this number is likely to be
underestimated.
In African Americans, the majority of BRCA1 mutations were not
observed in any other racial/ethnic group, implying these mutations
may be of African origin. In Hispanics, the most common BRCA1muta-
tions also were observed among individuals from other regions who
did not self-identify as Hispanic, including BRCA1 c.3331_3334del
(also observed in Australia, Europe, USA, and the UK), and BRCA1
c.68_69del (the Jewish founder mutation) (Weitzel et al., 2005, 2013).
The BRCA1 c.815_824dup mutation has been reported as being of
African origin, but has also been reported as a recurrent mutation in
Mexican Americans, perhaps as a reflection of the complex continen-
tal admixture of this population (Villarreal-Garza et al., 2015b). BRCA1
c.390C>Aandc.5496_5506delinsAweremost commonly found in the
Asian population. In BRCA2, c.2808_2811del was found among the 10
most frequent mutations in all races/ethnicities.
3.4 Recurrentmutations
As expected, the most common mutations in the entire data set
were the founder mutations BRCA1 c.5266dup (5382insC), BRCA1
c.68_69del (185delAG), and BRCA2 c.5946del (6174delT). In part, the
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F IGURE 2 Proportion of mutations in the breast cancer cluster regions (BCCR) and ovarian cancer cluster region (OCCR) in BRCA1 and
BRCA2 by ethnicity as defined previously (Rebbeck et al., 2015). Asterisk indicates proportion is significantly different than Caucasian proportion
(p-value< 0.05)
high frequencyof thesemutations is a consequenceof panels that facil-
itate testing for these three mutations in women of Jewish descent.
However, these two BRCA1 mutations also are relatively common in
regions with a low proportion of individuals who self-identify as Jew-
ish (e.g., Hungary,CzechRepublic, France,Germany, Italy, PolandSpain,
Russia, and UK). BRCA1 c.5266dup is a founder mutation thought to
haveoriginated1800years ago in Scandinavia/NorthernRussia, enter-
ing the Ashkenazi-Jewish population 400–500 years ago, and thus has
origins and a spread pattern independent of the Ashkenazim (Hamel
et al., 2011). Haplotype studies have been used to determine the origin
of BRCA1 c.68_69del in populations not considered to have a high pro-
portion of Jewish ancestry. In some populations, such as the Hispan-
ics in the USA and Latin American, it is associated with the Ashkenazi
Jewish haplotype, presumably due to unrecognized (Jewish) ances-
try (Ah Mew, Hamel, Galvez, Al-Saffar, & Foulkes, 2002; Velez et al.,
2012; Weitzel et al., 2005). In other populations, such as Pakistani
and Malaysians, where BRCA1 c.68_69del is a recurrent mutation, it
appears to have arisen independently, as it is carried on a distinct hap-
lotype (Kadalmani et al., 2007; Rashid et al., 2006). A different haplo-
type was also reported for several British families (the ‘Yorkshire hap-
lotype’) that is distinct from both the Jewish and the Indian-Pakistani
haplotypes (Laitman et al., 2013; Neuhausen et al., 1996).
The only locations inwhich these three foundermutationswere not
commonly observed were Belgium and Iceland. Iceland has another
founder mutation (i.e., BRCA2 c.771_775del). Yet other founder muta-
tions included BRCA1 c.4327C > T and BRCA2 c.8537_8538del in
Quebec. This latter mutation in BRCA2 also is the most commonmuta-
tion in high-risk families in Sardinia (Pisano et al., 2000) and was
also reported in a few Jewish Yemenite families, with a distinct hap-
lotype(Palomba et al., 2007). The BRCA1 c.181T > G mutation was
observed in Central Europe (Austria, Czech Republic, Germany, Hun-
gary, Italy and Poland), but also observed in the US, Argentina, Latvia,
Lithuania and Israel. Thismutation has been foundon a commonhaplo-
type in individuals of Polish and Ashkenazi Jewish ancestry, suggesting
it is an Eastern European founder mutation (Kaufman, Laitman, Gron-
wald, Lubinski, & Friedman, 2009). The large rearrangement muta-
tion in BRCA1 c.548-?_4185+?del (ex9-12del) appears to be an impor-
tant foundermutation inMexico, with findings of a common haplotype
and an estimated age at 74 generations (∼1,500 years) (Weitzel et al.,
2013).
We observed a number of other recurrent mutations. BRCA1
c.3331_3334del comprised more than half of all mutations identified
in Colombia, consistent with a previous report that this is a founder
mutation in the Colombian population (Torres et al., 2007). However,
this mutation has not been found at high rates in a second Colombian
population (Cock-Rada, et al., 2017). BRCA2 c.2808_2811del was fre-
quently observed, not only as the most common mutation in France
and Colombia, but also in other Western and Southern European
countries, and destinations to which individuals from these countries
have migrated. It estimated to have arisen approximately 80 (46–134)
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TABLE 2 Common BRCA1mutations by country of origin (by family)
Fivemost commonmutations (number observed)
Conti-nent Country Families
Unique
mutations 1 2 3 4 5
Africa Nigeria 20 15 c.303T>G(4) c.191G>A(2) c.3268C> T(2) c.4240dup(1) c.4122_4123del(1)
South Africa 49 16 c.2641G>T(18) c.5266dup(7) c.1374del(4) c.68_69del(4) c.3228_3229del(4)
Asia Hong Kong 70 45 c.470_471del(7) c.4372C> T(5) c.2635G> T(4) c.5406+1_5406+3del(4) c.3342_3345del(4)
Israel 679 7 c.68_69del(510) c.5266dup(151) c.2934T>G(13) c.181T>G(2) c.981_982del(1)
Korea 158 61 c.390C>A(19) c.5496_5506delinsA(17) c.922_924delinsT(11) c.5030_5033del(9) c.3627dup(8)
Malaysia 72 47 c.2635G> T(5) c.68_69del (4) c.470_471del(3) c.4148C>G(3) c.3770_3771del(3)
Pakistan 93 45 c.5503C> T(11) c. 3770_3771del(8) c.4508C>A(8) c.66dup(6) c.2269del(1)
Singapore 28 18 c.2726dup(9) c.2617dup(2) c.2635G> T(2) c.213-12A>G(1) c.3214del(1)
Turkey 1 1 c.3333del(1)
Australia Australia 581 173 c.68_69del(56) c.5266dup(45) c.4065_4068del (23) c.3756_3759del (22) c.5503C> T(16)
Europe Albania 1 1 c.4225C> T (1)
Europe Austria 391 115 c.181T>G(51) c.5266dup(46) c.3018_3021del(35) c.1687C> T(26) c.962G>A(17)
Belgium 166 41 c.2359dup(40) c.212+3A>G(26) c.3661G> T(12) c.3607C> T(10) c.3841C> T(9)
Bosnia 1 1 c.4158_4162del(1)
Czech Rep. 208 42 c.5266dup(87) c.3700_3704del(25) c.181T>G(20) c.1687C> T(16) c.3756_3759del(6)
Denmark 667 101 c.2475del(91) c.3319G> T(81) c.5266dup(41) c.3710del(39) c.5213G>A(30)
Finland 57 31 c.3485del(8) c.4097-2A>G (5) c 5266dup(4) c.1687C> (T42) c.4327C> T(3)
France 1,522 418 c.5266dup(118) c.3481_3491del(70) c.68_69del(63) c.4327C> T(49) c.3839_3843delins
AGGC (40)
Germany 2,287 381 c.5266dup(411) c.181T>G(196) c.4689C>G(63) c.1687C> T(62) c.3481_3491del(55)
Greece 208 41 c.5266dup(47) c.5212G>A(29) c.5406+644_*8273del(24) c.5468-285_5592+ 4019del
insCACAG(23)
c.5251C> T(13)
Hungary 235 47 c.5266dup(78) c.181T>G(60) c.68_69del(22) c.5278-?_5406+?del(5) c.5251C> T(4)
Iceland 3 1 c.5074G>A(3)
Ireland 2 2 c.547+1G> T(1) c.427G> T(1)
Italy 1,120 254 c.5266dup(124) c.181T>G(44) c.190T>C(43) c.1687C> T(39) c.1380dup(37)
Latvia 100 9 c.5266dup(49) c.4035del(40) c.181T>G(5) c.3756_3759del(1) c.4675G>A(1)
Lithuania 223 21 c.4035del(112) c.5266dup(58) c.181T>G221) c.1687C> T(5) c.5177_5180del(4)
Netherlands 782 126 c.5333-36_5406+
400del(87)
c.5277+1G>A(66) c.2685_2686del(60) c.2197_2201del(41) c.5266dup(40)
(Continues)
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TABLE 2 (Continued)
Fivemost commonmutations (number observed)
Conti-nent Country Families
Unique
mutations 1 2 3 4 5
Poland 1,064 8 c.5266dup(711) c.181T>G(276) c.4035del(69) c.5333-36_5406+400del(3) c.68_69del(2)
Portugal 49 23 c.3331_3334del(15) c.2037delinsCC(7) c.3817C> T(3) c.21A>G(2) c.5266dup(2)
Romania 1 1 c.5266dup(1)
Russia 160 10 c.5266dup(135) c.4035del(11) c.68_69del(7) c.5026_5027del(1) c.4185+2T>C(1)
Spain 678 181 c.211A>G(78) c.68_69del(62) c.5123C>A(61) c.3770_3771del(23) c.3331_3334del(23)
Sweden 438 108 c.3048_3052dup(68) c.1687C> T(31) c.2475del(27) c.1082_1092del(26) c.5266dup(19)
UK 1,389 297 c.68_69del(134) c.4065_4068del(104) c.4186-?_4357+?dup
(78)
c.3756_3759del(62) c.5266dup(60)
North America Canada 450 112 c.68_69del(99) c.4327C> T(66) c.5266dup(50) c.2834_2836delinsC(16) c.3756_3759del(12)
USA 4,219 613 c.68_69del(1130) c.5266dup(554) c.3756_3759del(113) c.4065_4068del(58) c.3756_3759(49)
Argentina 89 35 c.68_69del(22) c.5266dup(12) c.211A>G(11) c.181T>G(6) c.427G> T(3)
South/ Central
America
Brazil 101 39 c.5266dup(31) c.3331_3334del(18) c.135-?_441+?del(4) c.1687C> T(4) c.3916_3917del(3)
Colombia 55 2 c.3331_3334del(36) c.5123C>A(19)
Mexico 25 15 c.548-?_4185+?del(8) c.68_69del(2) c.824_825ins10(2) c.211A>G(2) c.5030_5033del(1)
Peru 1 1 c.4986+6T>C(1)
Venezuela 1 1 c.5123C>A(1)
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TABLE 3 Frequently observed BRCA2mutations by country of origin (by family)
Fivemost frequently observedmutations (number observed)
Conti-nent Country Families
Unique
mutations 1 2 3 4 5
Africa Nigeria 12 9 c.1310_1313del(3) c.8817_8820delA(2) c.5241_5242insTA(1) c.2402_2412del(1) c.994del(1)
South Africa 103 18 c.7934del(80) c.5946del(6) c.6944_6947del(2) c.5213_5216del(1) c.6939del(1)
Asia Hong Kong 91 45 c.3109C> T(22) c.2808_2811del(5) c.7878G>A(5) c.7007G> T(4) c.9294C>G(4)
Israel 339 5 c.5946del(330) c.8537_8538del(5) c.4936_4939del(2) c.3847_3848del(1) c.6024dup(1)
Japan 1 1 c.5645C>A(1)
Korea 220 93 c.7480C> T(40) c.3744_3747del(18) c.1399A> T(16) c.5576_5579del(14) c.6724_6725del(6)
Malaysia 64 47 c.262_263del(8) c.2808_2811del(3) c.3109C> T(3) c.5073dup(3) c.809C>G(2)
Pakistan 19 17 c.5222_5225del(3) c.8754+1G> T(1) c.92G>A(1) c.6468_6469del(1) c.2990T>G(1)
Philippines 1 1 c.2023del(1)
Qatar 1 1 c.7977-1G>C(1)
Saudi Arabia 1 1 c.473C>A(1)
Singapore 10 10 c.200_1910-877dup(1) c.2808_2811del(1) c.8961_8964del(1) c.8915del(1) c.956dup(1)
Australia Australia 496 178 c.5946del(53) c.6275_6276del(25) c.7977-1G>C(11) c.5682C>G(10) c.3487_3848del(10)
Europe Austria 185 87 c.8364G>A(17) c.8755-1G>A(15) c.3860del(11) c.1813dup(8) c.7846del(6)
Belgium 116 39 c.6275_6276del(17) c.516+1G> T(16) c.8904del(14) c.1389_1390del(9) c.3847_3848del(7)
Czech
Republic.
81 42 c.8537_8538del(12) c.7913_7917del(5) c.5645C>A(4) c.2808_2811del(4) c.9403del(4)
Denmark 442 101 c.7617+1G>A(61) c.6373del(44) c.1310_1313del (25) c.6486_6489del(25) c.3847_3848del(16)
Finland 52 16 c.9118-2A>G(18) c.7480C> T(12) c.771_775del(7) c.8327T>G(2) c.1286T>G(2)
France 997 375 c.2808_2811del(34) c.5946del(27) c.9026_9030del(22) c.8364G>A(22) c.5909C>A(19)
Germany 1,109 367 c.1813dup(51) c.3847_3848del(34) c.2808_2811del(29) c.5946del(29) c.5682C>G(23)
Greece 28 22 c.7976G>A(3) c.5722_5723del(2) c.9097dup(2) c.9501+1G>A(2) c.5722_5723del(2)
Hungary 81 39 c.9097dup(17) c.5946del(11) c. 7913_7917del(4) c.6656C>G(3) c.9403del(3)
Iceland 89 1 c.771_775del(89)
Ireland 2 2 c.8951C>G(1) c.5576_5579del(1)
Italy 706 242 c.8878C> T(33) c.6468_6469del(31) c.7180A> T(29) c.5682C>G(25) c.8247_8248delGA(18)
Lithuania 26 11 c.658_659del(13) c.3847_3848del(4) c.6580dup(1) c.6410del(1) c.7879A> T(1)
Netherlands 493 167 c.6275_6276del(38) c.8067T>A(26) c.5946del(25) c.9672dupA(23) c. 5213_5216del (21)
(Continues)
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TABLE 3 (Continued)
Fivemost frequently observedmutations (number observed)
Conti-nent Country Families
Unique
mutations 1 2 3 4 5
Norway 2 1 c.771_775del(2)
Poland 23 20 c.5946del(3) c.8946del(2) c. 7913_7917del(1) c.9294C>A(1) c.635_636del(1)
Portugal 71 22 c.156_157insAlu(39) c.9097dup(5) c.9382C> T(3) c.682-2A>C(2) c.5645G>A(2)
Romania 1 1 c.9097dup(1)
Russia 3 3 c.3682_3685del(1) c.5410_5411del(1) c.5946del(1)
Spain 670 217 c.3264dup(58) c.2808_2811del(56) c.9026_9030del(52) c.6275_6276del(32) c.9018C>A(16)
Sweden 123 68 c.4258del(11) c.2830A> T(7) c.1796_1800del(6) c.3847_3848del(6) c.7558C> T(5)
UK 1,200 308 c.6275_6276del(107) c.5946del(66) c.4478_4481del(37) c.755_758del(36) c.5682C>G(33)
North America Canada 311 108 c.8537_8538del(48) c.5946del(45) c.2808_2811del(13) c.6275_6276del(11) c.5857G> T(10)
USA 3,064 626 c.5946del(742) c.2808_2811del(86) c.1813dup(62) c.658_659del(50) c.6275_6276del(49)
Argentina 49 21 c.5946del(18) c.2808_2811del(5) c.6037A> T(4) c.9026_9030del(2) c.5645C>G(2)
Brazil 47 33 c.2T>G(5) c.2808_2811del(4) c.156_157insAlu(4) c.6405_6409del(3) c.1138del(2)
South/ Central
America
Colombia 19 4 c.2808_2811del(15) c.5851_5854del (2) c.6275_6276del(1) c.93G>A(1)
Costa Rica 1 1 c.9235del(1)
Honduras 1 1 c.7558C> T(1)
Mexico 6 6 c.3264dup (1) c.6275_6276del (1) c.2224C> T (1) c.5542del (1) c.6502G> T (1)
16 REBBECK ET AL.
F IGURE 3 BRCA1mutation distribution in African American, Asian, and Hispanic. Length of mutation indicator reflects the number of observed
mutations. Domains are zinc/ring finger (green); BRCT domain (red); BRCT (C terminus) (blue). Mutation type is indicated for each mutation by
color: green: missense mutations; black: truncating mutations (nonsense, nonstop, frameshift deletion, frameshift insertion, splice site, in-frame
mutations); purple: all other types of mutations
generations ago. However, due to the diversity of the haplotypes, mul-
tiple independent origins could not be ruled out (Neuhausen et al.,
1998). BRCA2 c.6275_6276del was a recurrent BRCA2 mutation in
Australia, theUK, Belgium, Spain, theNetherlands, andNorthAmerica.
This mutation has been estimated to have originated 52 (24–98) gen-
erations ago from a single founder (Neuhausen et al., 1998). Recurrent
or foundermutations were observed in diverse populations. For exam-
ple, the c.115T>G (Cys39Gly) mutation has been described in Green-
landers (Hansen et al., 2009). The c.2641G>T and c.7934del muta-
tions have both been reported as founder mutation in South African
Afrikaners (Reeves et al., 2004).
4 DISCUSSION
We have reported worldwide distribution of BRCA1 and BRCA2muta-
tions curated in the CIMBA dataset. These results may aid in the
understanding of the mutation distribution in specific populations as
well as imparting clinical and biological implications for our under-
standing of BRCA1- and BRCA2-associated carcinogenesis.
Clinical testing for BRCA1 and BRCA2mutations has benefited sub-
stantially from knowledge about common mutations in specific popu-
lations. In many countries, the three Ashkenazi-Jewish founder muta-
tions are offered as a mutation testing panel for self-reported Ashke-
nazim, based on their frequency. This approach is much less expensive
than comprehensive gene sequencing. The identification of commonly-
occurring mutations in other populations could lead to more efficient
and cost-effective mutation testing for BRCA1 and BRCA2. For exam-
ple, Villareal-Garza et al. (2015a) have developed the HISPANEL of
mutations that optimizes testing in Hispanic/Latino populations. In
the present study, we have identified mutations that may exist at a
sufficient prevalence to warrant consideration for population-specific
mutation testing panels. Criteria for developing such panels for BRCA1
and BRCA2 mutation screening are not available. However, muta-
tions that are in a specific population and that capture a sufficient
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F IGURE 4 BRCA2 mutation distribution in African American, Asian, and Hispanic CIMBA sample (per family). Length of mutation indicator
reflects the number of observed mutations. Domains are BRCA repeats (green); BRCA helica (red); OB binding domain (blue); tower (yellow) and
OB3 binding domain (purple). Mutation type is indicated for eachmutation by color: green: missense mutations; black: truncating mutations (non-
sense, nonstop, frameshift deletion, frameshift insertion, splice site, in-framemutations); purple: all other types of mutations
percentage of mutations in high risk individuals and families in that
population may be appropriate for use in targeted genetic testing.
Before such panels can be developed, population-based studies of
mutation frequency in specific populations should be undertaken. The
data reported herein provide a list of the recurrent mutations around
which such panels could be developed, but the frequencies are not
population based, particularly in settings where founder mutations
are preferentially screened (e.g., the Jewish founder panels). Similarly,
putative founder mutations identified by assessing common ancestral
origins of specific mutations (rather than just high prevalence; Table 5)
may form the basis of population-specific BRCA1 and BRCA2mutation
screening panels.
We report the distribution of BRCA1 and BRCA2 mutations in
nearly 30,000 families of bona-fide disease-associated mutations. The
strengths of this report include the large sample size that reflects a
geographically and racially/ethnically diverse set of BRCA1 and BRCA2
mutation carriers. However, some limitations need to be considered.
First, the sample set presented here does not reflect a systematic
study of these populations or races/ethnicities; the data reflect pat-
terns of recruitment (e.g., individuals with higher risk or prior diagno-
sis of cancer who consented to participate in research protocols) that
contributed to the CIMBA consortium. Certain racial/ethnic or socio-
demographic groups are under- or overrepresented or missing in our
data set and, as a consequence,mutationsmay be over- or underrepre-
sented. For example, the existence of a commercial panel of three Jew-
ish foundermutations enhances genetic testing for thosemutations.As
a result, the most frequently observed mutations in some populations
(e.g., the United States) reflect thewidespread use of this testing panel
in theUS population. Similar argumentsmay also apply for other popu-
lations, where testing for certain founder mutations may be more fre-
quent. Therefore, the relative frequencies of mutations by population
in the present study may be subject to such testing biases. Comparing
the relative frequencies is also complicated by the inclusion of related
individuals.
Second, although the CIMBA data represent most regions
around the world, there are limitations related to which groups of
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TABLE 4 Tenmost frequently observedmutations by self-identified race/ethnicity (%) (by family)
Mutation rank Caucasian African American Asian Hispanic/Latino Jewish Other
BRCA1 1 c.5266dup(17%) c.815_824dup(16%) c.390C>A(4%) c.68_69del(12%) c.68_69del(72%) c.5266dup(12%)
2 c.181T>G (6%) c.5324T>G (7%) c.5496_5506delinsA (3%) c.3331_3334del(10%) c.5266dup(24%) c.68_69del(17%)
3 c.68_69del(6%) c.5177_5180del(5%) c.470_471del(3%) c.5123C>A(9%) c.3756_3759del (0.3%) c.181T>G(5%)
4 c.4035del(2%) c.4357+1G>A(5%) c.5503C> T(2%) c.548-?_4185+?del(7%) c.1757del(0.3%) c.5333-36_5406+400del(3%)
5 c.4065_4068del(2%) c.190T>G(3%) c.922_924delinsT(2%) c.211A>G(5%) c.2934T>G(0.2%) c.3481_3491del(2%)
6 c.3756_3759del(2%) c.68_69del(3%) c.68_69del(2%) c.815_824del(3%) c.5503C> T(0.1%) c.1687C> T (2%)
7 c.1687C> T(2%) c.5467+1G>A(3%) c.3770_3771del(2%) c.2433del(3%) c.4185+1G> T(0.1%) c.4065_4068del(2%)
8 c.4327C> T(2%) c.182G>A(3%) c.2635G> T(2%) c.1960A> T(3%) c.4689C>G(0.1%) c.5277+1G>A (2%)
9 c.2475del(2%) c.5251C> T(2%) c.2726dup(2%) c.3029_3030del(3%) c.3770_3771del (0.1%) c.2685_2686del(68%)
10 c.4186-?_4357+?dup(1%) c.4484G> T(2%) c.3627dup(2%) c.4327C> T(2%) c.4936del(0.1%) c.4327C> T(1%)
Families 11,258 174 550 408 1,852 4,583
UniqueMutations 1,206 77 240 104 56 765
BRCA2 1 c.5946del(5%) c.2808_2811del(6%) c.7480C> T(8%) c.3264dup(17%) c.5946del(94%) c.5946del(5%)
2 c.6275_6276del(3%) c.4552del(6%) c.3109C> T(6%) c.2808_2811del(9%) c.3847_3848del (0.4%) c.6275_6276del(4%)
3 c.2808_2811del(3%) c.9382C> T(5%) c.3744_3747del(4%) c.145G> T(5%) c.1754del(0.4%) c.2808_2811del(3%)
4 c.771_775del(2%) c.1310_1313del(4%) c.1399A> T(3%) c.9026_9030del(3%) c.9382C> T(0.3%) c.1813dup(3%)
5 c.3847_3848del(2%) c.5616_5620del(4%) c.5576_5579del(3%) c.658_659del(3%) c.5621_5624del (0.2%) c.5645C>A(2%)
6 c.5682C>G(2%) c.6405_6409del(3%) c.2808_2811del(2%) c.5542del(3%) c.2808_2811del (0.2%) c.1310_1313del(2%)
7 c.1813dup(2%) c.658_659del(3%) c.7878G>A(2%) c.3922G> T(3%) c.4829_4830del (0.2%) c.3847_3848del(2%)
8 c.8537_8538del(1%) c.2957_2958insG(2%) c.262_263del(2%) c.1813dup(2%) c.5238del(0.2%) c.5682C>G(1%)
9 c.658_659del(1%) c.7024C> T(2%) c.7133C>G(1%) c.9699_9702del(2%) c.9207T>A(0.1%) c.9672dup(1%)
10 c.7934del(1%) c.6531_6534del(2%) c.5164_5165del(1%) c.6275_6276del(2%) c.3264dup(0.1%) c.658_659del(1%)
Families 7,156 125 538 207 990 2,551
UniqueMutations 1,242 77 248 91 44 753
R
E
B
B
E
C
K
E
T
A
L.
1
9
TABLE 5 Tenmost frequently observedmutations by continent of ascertainment (%) (by family)
Mutation rank North America Africa Asia South/Central America Europe Australia
BRCA1 1 c.68_69del(26%) c.2641G>T(26%) c.68_69del(47%) c.3331_3334del (20%) c.5266dup(17%) c.68_69del(10%)
2 c.5266dup(13%) c.5266dup(10%) c.5266dup(14%) c.5266dup(16%) c.181T>G(7%) c.5266dup(8%)
3 c.181T>G(3%) c.1374del(6%) c.390C>A(2%) c.68_69del(9%) c.68_69del(4%) c.4065_4068del(4%)
4 c.4327C> T(2%) c.68_69del(6%) c.5496_5506delinsA (2%) c.5123C>A(8%) c.4035del(2%) c.3756_3759del(4%)
5 c.4065_4068del(1%) c.3228_3229del(6%) c.5503C> T(1%) c.211A>G(5%) c.1687C> T(2%) c.5503C> T(3%)
6 c.3756_3759del(1%) c.303T>G(6%) c.2934T>G(1%) c.181T>G(3%) c.4065_4068del(2%) c.4186-?_4357+?dup(3%)
7 c.213-11T>G(1%) c.4838_4839insC (3%) c.3770_3771del(1%) c.548-?_4183+8?del(3%) c.3481_3491del(1%) c.4327C> T(2%)
8 c.1687C> T(1%) c.3268C> T(3%) c.2726dup(1%) c.1687C> T(2%) c.2475del(1%) c.5278-?_5592+?del (2%)
9 c.4186-?_4357+?dup(1%) c.1504_1508del(3%) c.470_471del(1%) c.135-?_441+?del(2%) c.3756_3759del(1%) c.70_80del(2%)
10 c.1175_1214del(1%) c.191G>A(3%) c.922_924delinsT(1%) c.5030_5033del (2%) c.3770_3704del(1%) c.1961del(2%)
Families 4,669 69 1,100 271 11,748 581
UniqueMutations 654 30 187 75 1282 173
BRCA2 1 c.5946del(23%) c.7934del(47%) c.5946del(34%) c.2808_2811del (11%) c.6275_6276del(2%) c.5946del(5%)
2 c.2808_2811del(3%) c.5946del(4%) c.7480C> T(4%) c.5946del(9%) c.5946del(2%) c.6275_6276del(2%)
3 c.8537_8538del(2%) c.1310_1313del(2%) c.3109C> T(3%) c.2T>G(2%) c.2808_2811del(2%) c.7977-1G>C(1%)
4 c.1813dup(2%) c.6944_6947del(1%) c.3744_3747del(2%) c.156_157insAlu (2%) c.771_775del(1%) c.5682C>G(1%)
5 c.6275_6276del(2%) c.8817_8820del(1%) c.1399A> T(2%) c.6037A> T(2%) c.3847_3848del(1%) c.3847_3848del(1%)
6 c.3847_3848del(3%) c.5213_5216del(1%) c.5576_5579del(2%) c.6405_6409del(3%) c.1813dup(1%) c.2808_2811del(1%)
7 c.658_659del(2%) c.6535_6536insA (1%) c.2808_2811del(1%) c.5645C>G(1%) c.5682C>G(1%) c.755_758del(1%)
8 c.9382C> T(1%) c.774_775del(1%) c.262_263del(1%) c.658_659del(1%) c.1310_1313del(1%) c.4478_4481del(1%)
9 c.3264dup(1%) c.6393del(1%) c.8537_8538del(1%) c.7180A> T(1%) c.5645C>A(1%) c.8297del(1%)
10 c.55073dup(1%) c.5042_5043del(1%) c.7878G>A(1%) c.5851_5854del (1%) c.9026_9030del(1%) c.250C> T(1%)
Families 3,375 170 976 222 10,175 1,047
UniqueMutations 660 27 187 58 1,315 179
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individuals have been tested and which centers contributed data. In
particular, non-White ancestry populations are still underrepresented
in research reports of mutation spectrum and frequency. Genetic
testing in the developing world remains limited.
Third, we presented the mutations in terms of type or effect
(Table 1), but these designations are not always based on experimental
evidence. For example, NMDmutation status is almost always defined
by a prediction rule rather than in vitro experiments that confirm the
presence of nonsensemediated decay.
Fourth, we presented the occurrence of putative founder muta-
tions. Someof these foundermutations (e.g.,BRCA1 c.68_69del,BRCA2
c.771_775del) have been demonstrated to be true founder mutations
based on actual ancestry analyses. Others, however, have only been
identified as occurring commonly in certain populations, but haplotype
or similar analyses of founder status may not have been done.
Fifth, our analysis was based on self-reported race/ethnicity of
studyparticipants, but this informationmaymisclassify somegroups of
individuals. For example, some Middle Eastern groups may have been
classified as “Caucasian” based on the data available, but in fact may
represent a distinct group that was not captured here. Moreover, in
some large centers participating in CIMBA, collecting information on
race/ethnicity is prohibited and thesemutation carriers were excluded
from the comparisons.
Finally, we evaluated mutations by racial/ethnic and geographic
designations, but some of these may be misclassified. For example,
while BRCA1 c.68_69del has been shown to arise independently of the
Jewish founder mutation in Pakistan (Rashid et al., 2006), we cannot
determine if the identified group also contains some Ashkenazi Jewish
individuals.
The data presented herein provide new insights into the world-
wide distribution of BRCA1 and BRCA2 mutations. The identifica-
tion of recurrent mutations in some racial/ethnic groups or geo-
graphical locations raises the possibility of defining more efficient
strategies for genetic testing. Three Jewish founder mutations BRCA1
c.5266dup (5382insC) and BRCA1 c.68_69del (185delAG) and BRCA2
c.5946del (6174delT) have long beenused as a primary genetic screen-
ing test for women of Jewish descent. The identification here of
other recurrent mutations in specific populations may similarly pro-
vide the basis for other mutation-specific panels. For example, BRCA1
c.5266dup (5382insC) may be useful as a single mutation screen-
ing test in Central-Eastern European populations before undertaking
full sequencing. However, this basic test may be supplemented with
screening forBRCA1 c.181T>G, as the secondmost commonmutation
of the region, and for some special cases, to includemost commonHun-
garian BRCA2 founder mutation c.9097dup (9326insA) for those with
Hungarian ancestry (Ramus et al., 1997b; van der Looij et al., 2000).
In Iceland, only two mutations were reported: the founder mutation
BRCA2 c.771_775del and the rarer BRCA1 c.5074G> A (Bergthorsson
et al., 1998). A number of other situations can be identified in which
specific mutations explain a large proportion of the total mutations
observed in a population. These and other such examples suggest that
targeted mutation testing panels that include specific mutations could
be developed for use in specific populations. Finally, we focused on
female BRCA1 and BRCA2 mutation carriers in this report. However,
the growing knowledge aboutBRCA1 andBRCA2-associated cancers in
men, particularly prostate cancer (Ostrander & Udler, 2008; Pritchard
et al., 2016), suggests that the information presented herein will also
have value in genetic testing of men.
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